PPBT — Purple Biotech Cashflow Statement
0.000.00%
- $6.81m
- -$0.09m
Annual cashflow statement for Purple Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -28.7 | -17.8 | -21.8 | -20 | -7.28 |
Depreciation | |||||
Non-Cash Items | 18.1 | 1.6 | 1.57 | -0.419 | -2.94 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -3.44 | 0.744 | 3.25 | 0.274 | -4.33 |
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -13.8 | -15.3 | -16.7 | -19.9 | -14.4 |
Capital Expenditures | -0.156 | -0.115 | -0.228 | -0.003 | 0 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -49.4 | 13.5 | 20.1 | 13.9 | 0.509 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -49.6 | 13.4 | 19.9 | 13.9 | 0.509 |
Financing Cash Flow Items | -5.38 | -0.099 | -0.219 | -0.946 | -0.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 68.5 | 1.51 | 1.11 | 5.45 | 6.77 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5.16 | -0.357 | 4.14 | -0.541 | -7.09 |